Effects of 1 to 3 years' treatment with alendronate on mechanical properties of the femoral shaft in a canine model: Implications for subtrochanteric femoral fracture risk
Open Access
- 24 April 2009
- journal article
- research article
- Published by Wiley in Journal of Orthopaedic Research
- Vol. 27 (10) , 1288-1292
Abstract
Bisphosphonate (BP) treatment used to prevent bone loss in postmenopausal osteoporosis has recently been implicated in an apparent increase in subtrochanteric femoral fractures. Previous work showed that BPs can reduce the energy to fracture of cancellous bone, but limited data exist on material‐level mechanical properties of compact bone from the long bones. This study examined intrinsic mechanical properties of the femoral diaphysis of a canine model treated for 1 or 3 years with alendronate at two different doses. Seventy‐two dogs were treated orally with 0.2 mg/kg/day alendronate or 1.0 mg/kg/day alendronate; a control group was administered saline. Prismatic beam specimens were tested in four‐point bending under displacement control, and the intrinsic mechanical properties were calculated. No significant differences were found among groups in any mechanical property at either 1 or 3 years of treatment. We conclude that the material properties of the femoral diaphysis are not degraded following 1 to 3 years treatment with alendronate, even at high doses. Longer periods of treatment have not been studied using clinical doses of alendronate, but such studies need to be carried out to confirm a lack of effect of alendronate on mechanical properties of cortical bone in the subtrochanteric region of the femur. © 2009 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 27:1288–1292, 2009Keywords
This publication has 33 references indexed in Scilit:
- Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronateOsteoporosis International, 2008
- Alendronate treatment results in similar levels of trabecular bone remodeling in the femoral neck and vertebraOsteoporosis International, 2008
- Alendronate Reduces Bone Toughness of Ribs without Significantly Increasing Microdamage Accumulation in Dogs Following 3 Years of Daily TreatmentCalcified Tissue International, 2008
- Low-Energy Femoral Shaft Fractures Associated With Alendronate UseJournal of Orthopaedic Trauma, 2008
- Three Years of Alendronate Treatment Results in Similar Levels of Vertebral Microdamage as After One Year of TreatmentJournal of Bone and Mineral Research, 2007
- Subtrochanteric insufficiency fractures in patients on alendronate therapyThe Journal of Bone and Joint Surgery. British volume, 2007
- Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronateBone, 2006
- Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog RibJournal of Bone and Mineral Research, 2004
- Long-Term Treatment of Incadronate Disodium Accumulates Microdamage but Improves the Trabecular Bone Microarchitecture in Dog VertebraJournal of Bone and Mineral Research, 2003
- Risedronate treatment does not increase microdamage in the canine femoral neckBone, 1995